Table 5.
Serum pharmacokinetic parameters for 5-day, multidose administration of the Mycograb C28Y variant in noninfected neutropenic mice (n = 3 in each cohort)a
| Dose (mg/kg/day) | Type of summary value | Cmax (ng/ml) | AUC (ng·h/ml) | t1/2α (min) | t1/2β (min) |
|---|---|---|---|---|---|
| 0.15 | Mean | 374.2 | 388.0 | 33.0 | 305.4 |
| Median | 330.7 | 360.9 | 28.8 | 119.1 | |
| CV%b | 24.1 | 20.3 | 49.4 | 107.6 | |
| 1.5 | Mean | 14,575.9 | 4,654.7 | 13.5 | 125.1 |
| Median | 5,520.7 | 3,036.2 | 13.1 | 135.9 | |
| CV% | 120.0 | 60.6 | 47.3 | 23.5 | |
| 15 | Mean | 16,969.4 | 18,961.4 | 41.7 | 1,468.9 |
| Median | 22,667.7 | 17,645.3 | 17.7 | 147.0 | |
| CV% | 64.0 | 13.9 | 111.7 | 156.7 |
a
The Mycograb C28Y variant was administered i.v. once daily for 5 days before the serum samples were collected.
b
CV%, coefficient of variation.